Precision BioSciences (Nasdaq:DTIL) - Stock Price, News & Analysis

DTIL Stock Overview

Precision BioSciences, Inc. es una empresa de edición genética avanzada que desarrolla en Estados Unidos terapias de edición genética in vivo para la eliminación, inserción y escisión de genes.

About the company

DTIL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Los beneficios han crecido 0.2% al año en los últimos 5 años.

Trading a buen valor en comparación con empresas similares e industria

Risk Analysis

Los accionistas se han diluido sustancialmente en el último año

Se prevé que los beneficios disminuyan una media de 9.9% al año durante los próximos 3 años.

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Volatilidad del precio de la acción en los últimos 3 meses

+ 1 more risk

Precision BioSciences, Inc. Competitors

Cue Biopharma

NasdaqCM:CUE

US$90.0m

Affimed

NasdaqCM:AFMD

US$98.7m

Emergent BioSolutions

NYSE:EBS

US$119.5m

Syros Pharmaceuticals

NasdaqGS:SYRS

US$123.5m

Price History & Performance

Summary of all time highs, changes and price drops for Precision BioSciences
Historical stock prices
Current Share Price	US$13.53
52 Week High	US$28.44
52 Week Low	US$8.25
Beta	1.57
1 Month Change	12.66%
3 Month Change	2.92%
1 Year Change	-41.06%
3 Year Change	-94.61%
5 Year Change	-96.58%
Change since IPO	-97.41%

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?

Sep 24

Precision BioSciences: The Right Profile To Progress

Aug 27

Shareholder Returns

	DTIL	US Biotechs	US Market
7D	-12.0%	-4.1%	-0.7%
1Y	-41.1%	4.0%	25.9%

Rentabilidad frente al sector: DTIL obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 5.8%.

Rentabilidad vs. Mercado: DTIL obtuvo unos resultados inferiores a los del mercado US, que fue del 22.3% el año pasado.

Price Volatility

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement	15.1%
Biotechs Industry Average Movement	11.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: DTILha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: DTIL(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2006	109	Michael Amoroso	https://www.precisionbiosciences.com

Precision BioSciences, Inc. es una empresa de edición genética avanzada que desarrolla terapias de edición genética in vivo para la eliminación, inserción y escisión de genes en Estados Unidos. La empresa ofrece ARCUS, una plataforma de edición genómica para la inserción, eliminación y reparación del genoma del ADN. También ofrece PBGENE-HBV para el tratamiento del virus de la hepatitis B crónica (VHB) para eliminar el ADN circular cerrado covalentemente con cortes y ediciones directas, así como para inactivar el ADN del VHB integrado con el objetivo de lograr reducciones duraderas del antígeno de superficie de la hepatitis B; PBGENE-PMM para el tratamiento de la miopatía mitocondrial primaria asociada a m.3243 (PMM) que se espera que presente un IND y/o CTA.

Precision BioSciences, Inc. Fundamentals Summary

How do Precision BioSciences's earnings and revenue compare to its market cap?
DTIL fundamental statistics
Market cap	US$98.69m
Earnings (TTM)	-US$42.53m
Revenue (TTM)	US$48.73m

1.9x

P/S Ratio

-2.2x

P/E Ratio

Is DTIL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DTIL income statement (TTM)
Revenue	US$48.73m
Cost of Revenue	US$0
Gross Profit	US$48.73m
Other Expenses	US$91.25m
Earnings	-US$42.53m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-6.15
Gross Margin	100.00%
Net Profit Margin	-87.28%
Debt/Equity Ratio	118.8%

How did DTIL perform over the long term?

See historical performance and comparison

DTIL Stock Overview

Rewards

Risk Analysis

Precision BioSciences, Inc. Competitors

NasdaqCM:CUE

US$90.0m

NasdaqCM:AFMD

US$98.7m

NYSE:EBS

US$119.5m

NasdaqGS:SYRS

US$123.5m

Price History & Performance

Recent News & Updates

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Recent updates

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precision Bio: Another CAR-T Laggard With No Solid Prospects

Precision BioSciences, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$12.50